# Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury

Study · id `cardio:ct-nct05399576` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05399576](<https://clinicaltrials.gov/study/NCT05399576>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05399576

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

## Technical summary

Registry record NCT05399576. Randomized; double masking; primary purpose prevention. Start 2022-05-17 (actual); primary completion 2023-05-17 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 150 participants (planned count; ClinicalTrials.gov record NCT05399576, source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)
- Started: 2022-05-17 (actual) (ClinicalTrials.gov record NCT05399576, source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)
- Primary completion: 2023-05-17 (anticipated) (ClinicalTrials.gov record NCT05399576, source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)
- Completion: 2023-09-17 (anticipated) (ClinicalTrials.gov record NCT05399576, source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05399576, source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05399576-2022-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury
- Condition: Coronary Artery Disease
- Intervention (Drug): Nicorandil
- Intervention (Drug): Saline
- Lead sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)

## Provenance

Content hash: ae00b12f73faabe955e3df9cd8a6572fbdffcd6a84f1f62a325c82e62b974900
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
